

Metal Enolates as Protecting Groups for Ketones During Metal Hydride Reduction

By D. H. R. BARTON,* R. H. HESSE, M. M. PECHET, and C. WILTSHIRE

(Research Institute for Medicine and Chemistry, Cambridge, Massachusetts 02142)

Summary Selective conversion of a ketone into a metal enolate is a convenient and efficient means of protecting such functions during metal hydride reductions.

SELECTIVE reduction of a specific carbonyl group in a molecule which bears a number of such functions is a problem frequently met in natural products chemistry. Although metal hydrides display differential reactivity with carbonyls in varying environments,¹ the most common approach has been the use of masking groups such as acetals, enamines, *etc.*, to protect selectively certain carbonyl functions.²


Recent studies have demonstrated the possibility of the selective conversion of steroidal ketones into metal enolates³ which might be expected to be inert to metal hydride reduction (*cf.* ref. 4). We now report that the selective conversion of specific ketones into metal enolates is a reliable and convenient means of protecting such functions during metal hydride reductions.

Prednisone BMD (**1a**) may be converted into the corresponding 1,3,5-trien-3-olate (**2**) by sodium or lithium bistrimethylsilylamide⁵ or trityl-lithium.⁶ These enolates may be reduced *in situ* with metal hydride to give good yields of prednisolone BMD (**1b**). Better yields are obtained with Ph_3CLi than with sodium or lithium bistrimethylsilylamide. The visible colour-change attending the protonolysis of Ph_3CLi is an added advantage of the use of this reagent. Studies of the stability of lithium enolates, particularly reactive bis enolates such as (**4**) derived from (**3a**), indicate that these intermediates decay rather rapidly when stored in solution at room temperature ($t_{1/2}$ ca. 3 h). Thus the reaction was carried out at -78° . The formation of the bis enolates derived from (**3a**) and (**7a**) did not reach completion quickly at -78° . In this case, it was necessary to allow the enolate reaction to warm to 0° . Following enolate formation the solution was then cooled to -78° and the reducing agent added.

Reduction was carried out with LiAlH_4 and the excess was destroyed with gaseous NH_3 . Compounds **1a**, **3a**, **5a**—**7a** were converted by this method into **1b**, **3b**, **5b**—**7b** respectively (40—75%). The conversion of (**5a**) into (**5b**) normally entails the reduction of an ester function as well as a ketone in the presence of a "masked" α,β -unsaturated ketone *via* three steps as in the commercial synthesis of hydrocortisone.⁷ The reduction of (**7a**) into (**7b**), which involves the protection of the corticosteroid side chain as an enolized 17,21-orthoester, is of significance as such orthoesters are normal intermediates in the synthesis of the commercially important 17-acyloxy- or 17,20-bisacyloxy-corticosteroid analogues.⁸

The conversion of (**6a**) into (**6b**) completes an alternative synthesis⁹ of the medicinally important 9α -fluoro- 11β -hydroxy steroids avoiding the $9(11)$ -ene and $9\beta,11\beta$ -epoxide as intermediates.

The major complication in the use of metal enolates as protecting groups is the tendency of enolized α,β -un-



saturated ketones to undergo protonation at the α -carbon 4—10 hydride equiv. of LiAlH_4 per mole of substrate. atom¹⁰ to give the unconjugated isomer.

All reactions were carried out under argon in THF using

(Received, 28th June 1972; Com. 1129.)

¹ (a) P. J. Neustaedter in 'Steroid Reactions,' ed. C. Djerassi, Holden-Day, San Francisco, 1963, pp. 135—148; (b) D. N. Kirk and M. P. Hartshorn, 'Steroid Reaction Mechanisms,' Elsevier, Amsterdam, 1968, pp. 135—143.

² H. J. E. Loewenthal, *Tetrahedron*, 1959, **6**, 269; J. F. W. Keana, ref. 1(a), pp. 2—65.

³ D. H. R. Barton, R. H. Hesse, G. Tarzia, and M. M. Pechet, *Chem. Comm.*, 1969, 1497; M. Tanabe and D. F. Crowe, *ibid.*, p. 1498.

⁴ N. M. Yoon and H. C. Brown, *J. Amer. Chem. Soc.*, 1968, **90**, 2927.

⁵ V. Wannagat and H. Niederprum, *Chem. Ber.*, 1961, **94**, 1540.

⁶ H. O. House and V. Kramer, *J. Org. Chem.*, 1963, **28**, 3362.

⁷ J. A. Hogg, P. F. Beal, A. H. Nathan, F. H. Lincoln, W. P. Schneider, B. J. Magerlein, A. R. Hanze, and R. W. Jackson, *J. Amer. Chem. Soc.*, 1955, **77**, 4436.

⁸ Glaxo Group Ltd., Netherland Patent No. 6608763 (June 27, 1966), *Chem. Abs.*, 1967, **67**, 82326f.

⁹ D. H. R. Barton, R. H. Hesse, M. M. Pechet, G. Tarzia, H. T. Toh, and N. D. Westcott, *Chem. Comm.*, 1972, 122, and references cited.

¹⁰ G. Kruger, *J. Org. Chem.*, 1968, **33**, 1750 and references cited.

¹¹ R. E. Beyer, F. Hoffman, R. M. Moriarty, and L. H. Sarrett, *J. Org. Chem.*, 1961, **26**, 2421.

¹² B. J. Magerlein and R. H. Levin, *J. Amer. Chem. Soc.*, 1953, **75**, 3654.